secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001193125-25-138481
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma stockholders approve reverse stock split at 1:5 to 1:25 ratio
-----------------------------------------------------------------------------

- Reverse stock split authorized at ratio between 1:5 and 1:25, board to set exact ratio.
- Three Class I directors elected: Heidi Hunter, Jon Wigginton, Michael Dybbs for three-year terms.
- Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 2025 with 99.1% for.
- Non-binding advisory vote on named executive officer compensation passed with 42.99M for.
- All proposals passed at June 6, 2025 annual meeting; broker non-votes ranged from 12.5M on director elections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525138481/0001193125-25-138481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525138481/d859738d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-138481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer